|Sativex||diabetes,neuropathy in humans via placebo trial (n=30)||Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor.||Oct 2009|
|Neutral There was significant improvement in pain scores in both groups, but mean change between groups was not significant. There were no significant differences in secondary outcome measures. Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.|
|cannabis||neuropathy,pain,hiv in humans via placebo trial (n=28/34)||Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial||Aug 2008|
Ingestion Method: Titration was started at 4% THC or placebo and adjusted incrementally downwards (to 2 or 1%) if side effects were intolerable, or upwards (to 6 or 8%) if pain relief was incomplete|
Positive Pain reduction was significantly greater with cannabis compared to placebo (median difference in pain reduction = 3.3 DDS points; effect size = 0.60; p = 0.016, all completers included; Figure 4). The results were consistent for the ITT analysis (p = 0.020), and for the comparison based on the first week of treatment alone (median change in DDS pain = -4.1 and 0.1 for the cannabis and placebo arms, p = 0.029). There were no evident sequence effects: the degree of pain relief achieved with active cannabis did not differ significantly according to whether it was administered during the first or the second treatment week (mean reduction in DDS points, 4.1 vs 0.96; p = 0.13).
|THC,CBD||ms,neuropathy in humans via placebo trial (n=64)||Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.||Sep 2007|
Ingestion Method: Sativex THC/CBD (27 mg/mL: 25 mg/mL) spray|
Positive THC/CBD was effective, with no evidence of tolerance, in these select patients with CNP and MS who completed approximately 2 years of treatment (n = 28).
|THC||diabetes,neuropathy in rats||Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress.||Dec 2009|
|These findings highlighted the beneficial effects of cannabis extract treatment in attenuating diabetic neuropathic pain, possibly through a strong antioxidant activity and a specific action upon nerve growth factor.|
|cannabis||pain,neuropathy in humans via trial (n=21/23)||Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.||Oct 2010|
Ingestion Method: 25mg THC|
Positive A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated.
|Geraniol||diabetes,neuropathy in rats via experiment||Protective effects of geraniol (a monoterpene) in a diabetic neuropathy rat model: Attenuation of behavioral impairments and biochemical perturbations||Sept 2014|
Ingestion Method: 100 mg/kg bw/day|
From our data, we hypothesize that GE may be a promising therapeutic candidate in the management of DN in humans.
|THC||neuropathy in mice||THC and gabapentin interactions in a mouse neuropathic pain model.||Jan 2019|
|These findings indicate that gabapentin synergistically enhances the anti-allodynic actions of THC and improves its therapeutic window. Thus, THC may represent a potential adjuvant for neuropathic pain medications such as gabapentin.|